Optimizing FLASH ultra‑high dose‑rate radiation to treat cancer with fewer side effects
Preclinical optimization of ultra-high dose rate (FLASH) radiotherapy parameters for translational relevance
Testing whether ultra‑high dose‑rate 'FLASH' radiation can control tumors while reducing harm to normal tissues for people with cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11212527 on NIH RePORTER |
What this research studies
This project refines how FLASH radiation is delivered so it can be used safely on patients in the future. Researchers compare FLASH beams and fractionation schedules to conventional radiation using preclinical tumor models and normal tissue tests. They will measure the dose needed to cure tumors (TCD50) and carefully track damage to surrounding organs like the brain, lungs, and gut. The goal is to find consistent beam and timing settings that give the protective FLASH effect without losing tumor control.
Who could benefit from this research
Good fit: Patients with solid tumors—especially cancers of the abdomen, brain, lung, or gastrointestinal tract—would be the likely candidates for future trials based on this work.
Not a fit: People with blood cancers, widely metastatic disease where local radiation is not appropriate, or those needing only systemic therapies are unlikely to benefit directly from this preclinical project in the near term.
Why it matters
Potential benefit: If successful, this work could enable radiation treatments that keep tumor control but cause fewer short‑ and long‑term side effects for cancer patients.
How similar studies have performed: Previous animal and preclinical studies have reported protective FLASH effects in several organs while maintaining tumor control, but results have been inconsistent and direct comparisons of cure doses (TCD50) are lacking.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Schueler, Emil — University of Tx Md Anderson Can Ctr
- Study coordinator: Schueler, Emil
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.